Recent SVA News
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 02/21/2024 11:09:13 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 11:02:10 AM
- Sinovac Amends Shareholder Rights Plan • Business Wire • 02/21/2024 07:56:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 02/02/2024 04:19:55 PM
- シノバック取締役会、一方的な部分公開買い付けを全会一致で退ける • Business Wire • 01/19/2024 11:58:00 AM
- Sinovac董事會一致反對Alternative Liquidity主動提出的部分公開收購方案 • Business Wire • 01/18/2024 07:54:00 PM
- Le conseil d'administration de Sinovac rejette à l'unanimité une offre partielle non sollicitée • Business Wire • 01/18/2024 07:47:00 PM
- Das Board of Directors von Sinovac lehnt einstimmig ein unaufgefordert abgegebenes Teilkaufangebot ab • Business Wire • 01/18/2024 06:33:00 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 01/18/2024 12:13:31 PM
- Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer • Business Wire • 01/18/2024 12:00:00 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 01/08/2024 09:46:34 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/04/2023 11:01:59 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 10/03/2023 01:39:57 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 09/15/2023 12:59:40 PM
- シノバック、新型コロナウイルスに対するSA55抗体注射剤の臨床試験について進展を報告 • Business Wire • 09/12/2023 10:10:00 AM
- SINOVAC rend compte des progrès réalisés dans le cadre de son essai clinique concernant l’injection anti-COVID-19 à base d’anticorps SA55 • Business Wire • 09/11/2023 02:36:00 PM
- SINOVAC informiert über die Fortschritte bei der klinischen Studie für den Anti-COVID-19-Antikörper SA55 Injection • Business Wire • 09/11/2023 02:36:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 10:16:45 AM
- SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection • Business Wire • 09/11/2023 09:55:00 AM
- シノバック取締役会、同意なき株式の部分公開買付を全会一致で拒否 • Business Wire • 09/06/2023 11:35:00 AM
- Sinovac-Vorstand lehnt ein unangefordertes Teilübernahmeangebot einstimmig ab • Business Wire • 09/05/2023 04:16:00 PM
- Le conseil d’administration de Sinovac rejette à l’unanimité une offre publique d’achat partielle non sollicitée • Business Wire • 09/05/2023 03:36:00 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 09/05/2023 11:04:01 AM
- Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer • Business Wire • 09/05/2023 08:12:00 AM
- シノバック、部分的な株式公開買付を一方的に受けたことを確認 • Business Wire • 08/29/2023 05:08:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM